{
    "clinical_study": {
        "@rank": "146415", 
        "acronym": "CARE", 
        "arm_group": {
            "arm_group_label": "Vascazen", 
            "arm_group_type": "Experimental", 
            "description": "Enrolled patients will receive four capsules daily of VASCAZEN (a 3.0 gram daily dose of EPA+DHA) for a total of 12 weeks."
        }, 
        "brief_summary": {
            "textblock": "The investigators aim to test the hypothesis that dietary supplementation with VASCAZEN will\n      correct omega-3 deficiency in cardiac rehab patients and improve biochemical risk factors."
        }, 
        "brief_title": "An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels", 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult subjects (> or = 18 years of age)\n\n          -  Enrolled in Cardiac Rehabilitation clinic with documented cardiovascular disease as\n             assessed by the principle investigator\n\n          -  Has had cardiovascular examination within the past 2 months\n\n        Exclusion Criteria:\n\n          -  Subjects who refuse to provide written consent\n\n          -  Subjects with medical conditions, as determined by the principal investigator, which\n             prevented them from study participation\n\n          -  Subjects with a known bleeding or clotting disorder\n\n          -  Subjects with known allergies to fish\n\n          -  Subjects with an implantable cardiac defibrillator\n\n          -  Subjects with a heart transplant\n\n          -  Female subjects who are currently taking hormone replacement therapy\n\n          -  Subjects who are pregnant or planning on becoming pregnant\n\n          -  Subjects currently taking Omega-3 fatty acid supplements (either under medical\n             supervision or self-administered)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02052986", 
            "org_study_id": "VCT-01"
        }, 
        "intervention": {
            "arm_group_label": "Vascazen", 
            "description": "All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA", 
            "intervention_name": "VASCAZEN", 
            "intervention_type": "Other"
        }, 
        "keyword": [
            "Fatty Acids, Omega-3", 
            "Omega-3 fatty acids", 
            "Docosahexaenoic acid (DHA)", 
            "Eicosapentaenoic acid (EPA)", 
            "Docosapentaenoic acid (DPA)", 
            "Omega Index", 
            "Omega Score", 
            "Cardiac Rehab"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "link": {
            "description": "WebMD", 
            "url": "http://www.webmd.com/drugs/drug-160617-Vascazen+Oral.aspx?drugid=160617&drugname=Vascazen+Oral"
        }, 
        "location": {
            "contact": {
                "email": "brm9071@nyp.org", 
                "last_name": "Brian Marino, DO", 
                "phone": "814-404-4169"
            }, 
            "facility": {
                "address": {
                    "city": "Fresh Meadows", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11365"
                }, 
                "name": "The NYHQ Cardiac Health Center"
            }, 
            "investigator": [
                {
                    "last_name": "Todd Kerwin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Barbara Pistone, RD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "other_outcome": [
            {
                "measure": "Change in Omega-3 Score and Omega-3 Index", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 weeks, 12 weeks"
            }, 
            {
                "measure": "Change in high-sensitivity C-reactive protein (hsCRP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 weeks, 12 weeks"
            }, 
            {
                "measure": "Change in blood levels of total cholesterol, low-density lipoprotein (LDL), high density lipoprotein (HDL), very-low density lipoprotein (VLDL) cholesterol and their subfractions (particle size)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 weeks, 12 weeks"
            }, 
            {
                "measure": "Change in blood level of Triglycerides", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 weeks, 12 weeks"
            }, 
            {
                "measure": "Change in fasting plasma glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline,12 weeks"
            }, 
            {
                "measure": "Change in blood glucose and insulin measurements following administration of oral glucose tolerance test (OGTT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks"
            }, 
            {
                "measure": "Change in glycated hemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline,12 weeks"
            }, 
            {
                "measure": "Change in Lipoprotein associated Phospholipase (Lp-PLA2)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6 weeks, 12 weeks"
            }
        ], 
        "overall_contact": {
            "email": "brm9071@nyp.org", 
            "last_name": "Brian S Marino, DO", 
            "phone": "814-404-4169"
        }, 
        "overall_contact_backup": {
            "email": "djc9001@nyp.org", 
            "last_name": "Donna Cheslik, RN, MSN", 
            "phone": "718-670-1695"
        }, 
        "overall_official": {
            "affiliation": "New York Hospital Queens", 
            "last_name": "Brian S Marino, DO", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in the sum of the subject's blood Eicosapentaenoic acid (EPA) + Docosahexaenoic acid (DHA) + Docosapentaenoic acid (DPA) levels (Omega-Score) and the change in the sum of the subject's red blood cell (RBC) EPA + DHA levels (Omega-Index) over 12 weeks of study treatment with Vascazen", 
            "measure": "Change in sum of Omega-Score and Omega-Index", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "reference": [
            {
                "PMID": "11948270", 
                "citation": "Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med. 2002 Apr 11;346(15):1113-8."
            }, 
            {
                "PMID": "10465168", 
                "citation": "[No authors listed] Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999 Aug 7;354(9177):447-55. Erratum in: Lancet. 2007 Jan 13;369(9556):106. Lancet 2001 Feb 24;357(9256):642."
            }, 
            {
                "PMID": "16919519", 
                "citation": "Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006 Aug 21;98(4A):71i-76i. Epub 2006 May 30. Review."
            }, 
            {
                "PMID": "10799369", 
                "citation": "Mori TA, Burke V, Puddey IB, Watts GF, O'Neal DN, Best JD, Beilin LJ. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr. 2000 May;71(5):1085-94."
            }, 
            {
                "PMID": "9280188", 
                "citation": "Grimsgaard S, Bonaa KH, Hansen JB, Nord\u00f8y A. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997 Sep;66(3):649-59."
            }, 
            {
                "PMID": "12172309", 
                "citation": "Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens. 2002 Aug;20(8):1493-9."
            }, 
            {
                "PMID": "12583947", 
                "citation": "Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):477-85."
            }, 
            {
                "PMID": "12438303", 
                "citation": "Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002 Nov 19;106(21):2747-57. No abstract available. Erratum in: Circulation. 2003 Jan 28;107(3):512."
            }, 
            {
                "PMID": "15208005", 
                "citation": "Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004 Jul;39(1):212-20."
            }, 
            {
                "PMID": "17876200", 
                "citation": "von Schacky C, Harris WS. Cardiovascular risk and the omega-3 index. J Cardiovasc Med (Hagerstown). 2007 Sep;8 Suppl 1:S46-9. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02052986"
        }, 
        "responsible_party": {
            "investigator_affiliation": "New York Hospital Queens", 
            "investigator_full_name": "Brian S. Marino, DO", 
            "investigator_title": "Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Change in patient health questionnaire-9 (PHQ-9) depression scale after 12 weeks of study treatment", 
            "measure": "Change in patient health questionnaire-9 (PHQ-9) depression scale", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "source": "New York Hospital Queens", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "NYHQ Cardiac Health Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Pivotal Therapeutics", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "New York Hospital Queens", 
                "agency_class": "Other"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}